Company: IXHL
Filing Date: 2025-09-29
Form Type: 10-K
Source: 0001213900-25-092837
Chunk: 180

Company: Incannex Healthcare Inc.
Filing Date: 2025-09-29
Form: 10-K
Item: Item 1
Chunk 180
---
 infringement proceeding, a court may decide that a patent of ours is invalid in
whole or in part, unenforceable, or construe the patent’s claims narrowly allowing the other party to commercialize competing products
on the grounds that our patents do not cover such products.

Even if resolved in our favor, litigation or other
legal proceedings relating to intellectual property claims may cause us to incur significant expenses and could distract our technical
and management personnel from their normal responsibilities. Such litigation or proceedings could substantially increase our operating
losses and reduce our resources available for development activities. We may not have sufficient financial or other resources to adequately
conduct such litigation or proceedings. Some of our competitors may be able to sustain the costs of such litigation or proceedings more
effectively than we can because of their substantially greater financial resources. The effects of patent litigation or other proceedings
could therefore have a material adverse effect on our ability to compete in the marketplace.

Issued patents covering our drug candidates, compositions or
uses could be found invalid or unenforceable if challenged in a patent office or court.

Even if our patents or our past, current or future
collaboration partners’ or licensors’ patents do successfully issue and even if such patents cover our technologies, drug
candidates, compositions or methods of use, third parties may initiate interference, re-examination, post-grant review, inter partes review
(“IPR”) or derivation actions in the USPTO; may initiate third party oppositions in the EPO; or may initiate similar actions
challenging the validity, enforceability, scope or term of such patents in other patent administrative or court proceedings worldwide,
which may result in patent claims being narrowed or invalidated. Such proceedings could result in revocation or amendment of our patents
in such a way that they no longer cover competitive technologies, drug candidates, compositions or methods of use. Further, if we initiate
legal proceedings against a third party to enforce a patent covering our technologies, drug candidates, compositions or uses, the defendant
could counterclaim that our relevant patent is invalid or unenforceable. In patent litigation in the United States, certain European and
other countries worldwide, it is commonplace for defendants to make counterclaims alleging invalidity and unenforceability in the same
proceeding, or to commence parallel defensive proceedings such as patent nullity actions to challenge validity and enforceability of asserted
patent claims. Further, in the United States, a third party, including a licensee of one of our past